DB:P6NP

Stock Analysis Report

Executive Summary

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases.


Snowflake Analysis

Adequate balance sheet and fair value.

Share Price & News

How has Acer Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: P6NP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

12.5%

P6NP

6.7%

DE Pharmaceuticals

9.1%

DE Market


1 Year Return

n/a

P6NP

-5.4%

DE Pharmaceuticals

-13.1%

DE Market

Return vs Industry: Insufficient data to determine how P6NP performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how P6NP performed against the German Market.


Shareholder returns

P6NPIndustryMarket
7 Day12.5%6.7%9.1%
30 Day-37.9%-3.5%-1.0%
90 Day-49.4%-19.8%-20.7%
1 Yearn/a-2.2%-5.4%-10.6%-13.1%
3 Yearn/a21.5%7.8%-10.7%-18.1%
5 Yearn/a14.6%-5.0%-10.7%-22.8%

Price Volatility Vs. Market

How volatile is Acer Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Acer Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: P6NP (€1.89) is trading below our estimate of fair value (€89.45)

Significantly Below Fair Value: P6NP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: P6NP is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: P6NP is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate P6NP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: P6NP is good value based on its PB Ratio (1x) compared to the DE Pharmaceuticals industry average (1.8x).


Next Steps

Future Growth

How is Acer Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

50.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: P6NP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: P6NP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: P6NP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if P6NP's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if P6NP's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if P6NP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Acer Therapeutics performed over the past 5 years?

-44.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: P6NP is currently unprofitable.

Growing Profit Margin: P6NP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: P6NP is unprofitable, and losses have increased over the past 5 years at a rate of -44.3% per year.

Accelerating Growth: Unable to compare P6NP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: P6NP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.2%).


Return on Equity

High ROE: P6NP has a negative Return on Equity (-160.14%), as it is currently unprofitable.


Next Steps

Financial Health

How is Acer Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: P6NP's short term assets ($12.9M) exceed its short term liabilities ($2.8M).

Long Term Liabilities: P6NP's short term assets ($12.9M) exceed its long term liabilities ($326.3K).


Debt to Equity History and Analysis

Debt Level: P6NP is debt free.

Reducing Debt: P6NP had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: P6NP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: P6NP has less than a year of cash runway if free cash flow continues to reduce at historical rates of -43.8% each year


Next Steps

Dividend

What is Acer Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate P6NP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate P6NP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if P6NP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if P6NP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of P6NP's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Chris Schelling (43yo)

2.58s

Tenure

US$1,467,211

Compensation

Mr. Christopher Schelling, also known as Chris, Founded Acer Therapeutics Inc. in December 2013 and has been its President and Chief Executive Officer since September 2017 and served as its Chief Operating ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD1.47M) is above average for companies of similar size in the German market ($USD423.01K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Schelling
Founder2.58yrsUS$1.47m17.34% $3.2m
Harry Palmin
COO & CFO4.17yrsUS$844.44k1.24% $225.2k
William Andrews
Chief Medical Officer2.5yrsUS$1.09m0.058% $10.6k
John Klopp
Chief Technical Officer0.58yrno datano data
Donald Joseph
Chief Legal Officer & Secretary2yrsno datano data
Jeannie Kim
Vice President of Corporate Development1.5yrsno datano data
Matthew Seibt
Chief Commercial Officer1.08yrsno datano data
Jason Kneeland
VP of Finance & Controllerno datano datano data

2.0yrs

Average Tenure

48.5yo

Average Age

Experienced Management: P6NP's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Schelling
Founder2.58yrsUS$1.47m17.34% $3.2m
Stephen Aselage
Independent Chairman of the Board2.58yrsUS$159.09k0.19% $34.1k
Michelle Griffin
Independent Director2.58yrsUS$140.34kno data
Stuart Swiedler
Member of the Scientific Advisory Boardno datano datano data
John Dunn
Independent Director2.58yrsUS$135.34k0.059% $10.7k
Thomas Fleming
Member of the Scientific Advisory Boardno datano datano data
Jason Amello
Independent Director2.58yrsUS$127.84kno data
Marlene Haffner
Member of the Scientific Advisory Boardno datano datano data
Brendan Lee
Member of the Scientific Advisory Boardno datano datano data
Gerard Berry
Member of the Scientific Advisory Boardno datano datano data

2.6yrs

Average Tenure

62yo

Average Age

Experienced Board: P6NP's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18%.


Top Shareholders

Company Information

Acer Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Acer Therapeutics Inc.
  • Ticker: P6NP
  • Exchange: DB
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$19.887m
  • Listing Market Cap: US$18.187m
  • Shares outstanding: 10.10m
  • Website: https://www.acertx.com

Number of Employees


Location

  • Acer Therapeutics Inc.
  • One Gateway Center
  • Suite 351
  • Newton
  • Massachusetts
  • 2458
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
P6NPDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2017
ACERNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2017

Biography

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/10 08:17
End of Day Share Price2020/04/09 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.